|
Humacyte, Inc. (HUMA) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Humacyte, Inc. (HUMA) Bundle
Looking to assess the intrinsic value of Humacyte, Inc.? Our HUMA DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and make more informed investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5 | 1.3 | 1.6 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -15.29 | 23.91 | -100 | 0 | -22.85 | -22.85 | -22.85 | -22.85 | -22.85 |
| EBITDA | -56.2 | -73.0 | 2.5 | -96.5 | -114.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -3772.57 | -5777.28 | 159.11 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | 8.4 | 8.3 | 8.3 | 7.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 565.53 | 655.82 | 527.48 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -64.7 | -81.2 | -5.8 | -104.2 | -114.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -4338.1 | -6433.1 | -368.37 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 39.9 | 225.5 | 151.9 | 80.4 | 44.9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 7.58 | 13.94 | 1.98 | 100 | 100 | 44.7 | 44.7 | 44.7 | 44.7 | 44.7 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0.000067069081 | 0.000079176564 | -1.98 | 100 | 100 | 39.6 | 39.6 | 39.6 | 39.6 | 39.6 |
| Accounts Payable | 2.3 | 2.1 | 1.6 | 6.5 | 4.5 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 152.52 | 165.8 | 101.92 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.3 | -.2 | -1.0 | -2.3 | -1.6 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -21.33 | -17.42 | -66.96 | 100 | 100 | -21.14 | -21.14 | -21.14 | -21.14 | -21.14 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -66.8 | 115.2 | 30.9 | -104.2 | -114.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -56.5 | 123.0 | 37.8 | -93.8 | -118.0 | -4.5 | .0 | .0 | .0 | .0 |
| WACC, % | 11.8 | 11.8 | 11.8 | 11.8 | 11.8 | 11.8 | 11.8 | 11.8 | 11.8 | 11.8 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | -28 | |||||||||
| Equity Value | 24 | |||||||||
| Diluted Shares Outstanding, MM | 118,479 | |||||||||
| Equity Value Per Share | 0.00 |
What You Will Get
- Pre-Filled Financial Model: Humacyte’s actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
- Instant Calculations: Automatic updates ensure you see results as you make changes.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.
Key Features
- 🔍 Real-Life HUMA Financials: Pre-filled historical and projected data for Humacyte, Inc. (HUMA).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Humacyte’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Humacyte’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download the Template: Gain immediate access to the Excel-based HUMA DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Humacyte’s intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial strategies.
Why Choose This Calculator for Humacyte, Inc. (HUMA)?
- Accurate Data: Up-to-date Humacyte financials provide trustworthy valuation outcomes.
- Customizable: Tailor essential variables like growth rates, WACC, and tax rates to suit your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Investors: Accurately assess Humacyte's fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis.
- Consultants: Easily customize the template for valuation reports tailored to clients.
- Entrepreneurs: Acquire insights into financial modeling practices used by leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation methodologies.
What the Template Contains
- Historical Data: Includes Humacyte’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Humacyte’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Humacyte’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.